— Know what they know.
Not Investment Advice

MDT vs SYK vs ABT

161 measures in 16 categories, one definition each, computed from filings and market data.
MDT63.6
Medtronic Plc
Healthcare · Medical - Devices
$94.75 −0.73%$121.2B mkt cap
Score DNA
SYK73.6
Stryker Corporation
Healthcare · Medical - Devices
$294.66 +0.49%$113.0B mkt cap
Score DNA
ABT56.6
Abbott Laboratories
Healthcare · Medical - Devices
$104.88 +0.20%$181.5B mkt cap
Score DNA

Price, rebased to 100 three years ago

MDT   SYK   ABT   · weekly adjusted closes
100120140160Jan 24Apr 24Jul 24Oct 24Jan 25Apr 25Jul 25Oct 25Jan 26Apr 26Jul 26Oct 26MDT 145ABT 120SYK 116
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.

Smart money

8 measures
MeasureMDTSYKABT
Insider open-market buys, 180d 0 0 3
Insider $ bought, 180d — — $1.30M
Congress purchases, 180d 2 1 13
Last Congress purchase 2026-09-11 2026-09-04 2026-09-18
13F net change in holders −94 −37 −134
ETFs adding shares, 30d 567 1,328 1,517
ETFs trimming, 30d 485 980 1,197
Net ETF funds, 30d +82 +348 +320

Valuation

16 measures
MeasureMDTSYKABT
P/E (TTM) 23.2x
41st
30.3x
56th
33.5x
67th
PEG (P/E ÷ 3-yr EPS CAGR) 1.60
60th
2.75
80th
18.41
100th
Price / sales 3.2x
48th
4.4x
72nd
3.9x
62nd
Price / book 2.4x
36th
4.7x
62nd
3.6x
54th
Price / tangible book — — —
Price / free cash flow 19.8x
36th
24.0x
44th
20.8x
39th
Price / operating cash flow 15.1x
28th
20.5x
53rd
18.3x
40th
Enterprise value $140.5B
98th
$124.5B
97th
$208.5B
100th
EV / sales 3.7x
57th
4.8x
73rd
4.5x
65th
EV / EBITDA 13.8x
42nd
18.6x
50th
19.0x
53rd
EV / EBIT 19.2x
33rd
22.9x
45th
26.1x
58th
EV / free cash flow 22.9x
36th
26.5x
47th
23.9x
39th
Earnings yield 4.3%
82nd
3.3%
75th
3.0%
70th
FCF yield 5.1%
78th
4.2%
73rd
4.8%
77th
Operating cash flow yield 6.6%
80th
4.9%
62nd
5.5%
72nd
Graham number (per share) $59.83
74th
$116.22
93rd
$45.32
56th

Profitability (TTM)

12 measures
MeasureMDTSYKABT
Gross margin 66.7%
57th
65.2%
52nd
56.8%
38th
EBITDA margin 27.1%
90th
25.9%
87th
23.5%
82nd
Operating margin 18.1%
85th
22.0%
93rd
17.0%
83rd
EBIT margin 19.5%
85th
21.1%
88th
17.2%
82nd
Net margin 13.9%
85th
14.4%
87th
11.6%
80th
NOPAT margin 14.4%
82nd
16.0%
85th
12.3%
73rd
FCF margin 16.3%
80th
18.2%
83rd
18.7%
88th
Operating cash flow margin 21.4%
87th
21.4%
85th
21.3%
83rd
R&D / revenue 7.8%
39th
6.4%
31st
6.8%
34th
SG&A / revenue 32.4%
18th
34.0%
27th
28.9%
15th
Stock comp / revenue 1.3%
23rd
1.0%
15th
1.5%
30th
Effective tax rate 20.2%
19th
27.6%
88th
27.8%
90th

Returns on capital

11 measures
MeasureMDTSYKABT
ROE (on average equity) 10.7%
69th
16.5%
86th
10.7%
71st
ROA 5.7%
72nd
7.9%
80th
5.6%
70th
ROIC 7.8%
66th
11.6%
73rd
7.3%
63rd
ROCE 9.0%
72nd
13.2%
87th
8.8%
70th
Return on tangible assets 8.0%
70th
11.6%
87th
8.3%
73rd
Cash ROIC (OCF / invested capital) 11.6%
61st
15.6%
69th
12.7%
68th
Gross profitability (GP / assets) 26.8%
33rd
35.1%
47th
24.2%
22nd
ROIC, 3-yr average 6.0%
65th
8.7%
73rd
10.8%
80th
ROIC, 5-yr average 6.7%
65th
10.0%
71st
13.9%
82nd
ROE, 5-yr average 9.1%
73rd
15.1%
81st
17.9%
85th
Incremental ROIC 90.1%
84th
328.7%
92nd
-22.2%
33rd

Growth

17 measures
MeasureMDTSYKABT
Revenue growth (TTM YoY) 9.8%
45th
8.5%
39th
8.1%
38th
Revenue growth (QoQ) -0.5%
13th
9.5%
58th
12.8%
70th
Revenue CAGR, 3 yr 6.0%
28th
9.9%
43rd
5.0%
23rd
Revenue CAGR, 5 yr 3.5%
15th
9.7%
38th
3.0%
12th
Gross profit CAGR, 3 yr 6.5%
29th
13.1%
56th
9.9%
38th
Operating income CAGR, 3 yr 6.4%
32nd
12.8%
52nd
9.4%
40th
Net income growth (TTM YoY) 12.2%
58th
27.8%
62nd
-61.2%
8th
Net income CAGR, 3 yr 13.1%
50th
11.2%
45th
1.7%
30th
EPS growth (TTM YoY) 12.4%
58th
27.9%
62nd
-61.0%
8th
EPS CAGR, 3 yr 14.5%
50th
11.0%
35th
1.8%
25th
EPS CAGR, 5 yr 7.3%
45th
12.1%
65th
-2.6%
20th
FCF growth (TTM YoY) 15.6%
47th
16.8%
50th
28.7%
57th
FCF CAGR, 3 yr 11.3%
19th
24.8%
42nd
16.7%
31st
Operating cash flow CAGR, 3 yr 11.3%
39th
22.2%
58th
9.9%
32nd
Book value CAGR, 3 yr 0.6%
37th
11.2%
63rd
11.3%
67th
Dividend CAGR, 3 yr 1.7%
25th
1.5%
12th
2.5%
50th
Sustainable growth rate 3.2%
15th
10.7%
48th
2.3%
4th

Margin history & stability

7 measures
MeasureMDTSYKABT
Gross margin, 3-yr average 65.1%
51st
62.9%
45th
53.4%
26th
Operating margin, 3-yr average 17.3%
89th
22.0%
94th
16.9%
87th
Net margin, 3-yr average 13.2%
85th
14.3%
87th
19.2%
94th
FCF margin, 3-yr average 15.9%
87th
16.1%
89th
16.1%
91st
Revenue stability (0-1) 0.73
21st
0.99
92nd
0.69
17th
Earnings stability (0-1) 0.17
32nd
0.81
85th
0.04
6th
Margin stability (0-1) 0.98
89th
0.97
68th
0.95
40th

Liquidity (latest quarter)

7 measures
MeasureMDTSYKABT
Cash & short-term investments $8.8B
100th
$3.5B
95th
$5.6B
98th
Net cash (− = net debt) −$19.3B
2nd
−$11.5B
5th
−$27.0B
0th
Working capital $12.6B
100th
$7.7B
98th
$6.7B
97th
Current ratio 2.07
30th
2.16
33rd
1.38
8th
Quick ratio 2.09
45th
1.33
27th
0.97
12th
Cash ratio (cash + ST investments / current liabilities) 0.75
43rd
0.52
30th
0.31
22nd
Defensive interval (days) 181 days
17th
236 days
27th
279 days
43rd

Leverage & solvency (latest quarter)

13 measures
MeasureMDTSYKABT
Total debt $28.2B
98th
$14.9B
97th
$32.6B
100th
Debt / equity 0.56
53rd
0.62
56th
0.64
58th
Net debt / equity 0.38
58th
0.48
60th
0.53
65th
Debt / assets 30.2%
57th
31.2%
58th
29.9%
53rd
Debt / capital 35.9%
53rd
38.4%
56th
38.9%
58th
Debt / EBITDA 2.77
53rd
2.23
45th
2.98
58th
Net debt / EBITDA 1.90
47th
1.71
45th
2.46
58th
Interest coverage (EBIT / interest) 10.1x
81st
6.6x
77th
12.6x
87th
Cash interest coverage 11.1x
83rd
6.7x
71st
15.5x
90th
Debt payback (years of OCF) 3.5 yrs
51st
2.7 yrs
40th
3.3 yrs
49th
Liabilities / assets 45.5%
45th
50.0%
53rd
52.6%
57th
IS credit model rating AA- AA- A+
Implied credit spread (bps) 100
22nd
100
22nd
125
28th

Efficiency

11 measures
MeasureMDTSYKABT
Asset turnover 0.41
15th
0.55
37th
0.48
23rd
Fixed asset turnover — 5.77
64th
3.64
24th
Inventory turnover — 1.7
41st
2.8
78th
Receivables turnover 11.6
100th
6.7
62nd
5.6
32nd
Days sales outstanding 32 days
0th
54 days
38th
65 days
68th
Days inventory outstanding — 219 days
59th
129 days
22nd
Days payables outstanding 77 days
68th
63 days
57th
83 days
75th
Cash conversion cycle (days) −54 days
3rd
210 days
48th
112 days
20th
Capex / revenue 5.1%
69th
3.2%
45th
2.5%
29th
Capex / depreciation 0.67
50th
0.66
48th
0.40
21st
Operating expense ratio 46.9%
25th
43.1%
19th
43.8%
20th

Cash flow & earnings quality

7 measures
MeasureMDTSYKABT
Operating cash flow / net income 1.54
44th
1.48
41st
1.83
70th
FCF / net income 1.17
44th
1.26
48th
1.61
78th
FCF / operating cash flow 76.3%
62nd
85.1%
76th
88.0%
83rd
Capex / operating cash flow 23.7%
38th
14.9%
24th
12.0%
17th
Accruals ratio -3.0%
72nd
-3.8%
68th
-4.6%
52nd
Sloan accruals ratio -2.1%
45th
1.6%
68th
-7.5%
25th
Earnings quality score (0-1) 1.00
48th
1.00
48th
1.00
48th

Dividends & buybacks

9 measures
MeasureMDTSYKABT
Dividend yield 3.0%
100th
1.2%
93rd
2.4%
97th
Dividend per share (TTM) $2.86
98th
$3.52
100th
$2.52
97th
Payout ratio (dividends / net income) 69.8%
96th
35.3%
85th
78.5%
100th
Dividends / FCF 59.5%
97th
28.0%
83rd
48.9%
89th
Dividend growth (YoY) 1.5%
33rd
5.4%
56th
7.7%
67th
Buyback yield 1.0%
72nd
0.1%
65th
1.0%
73rd
Shareholder yield (dividends + buybacks) 4.0%
95th
1.3%
70th
3.4%
87th
Share count change (YoY) -0.2%
34th
-0.1%
36th
-0.5%
32nd
Buybacks, last 5 years $4.9B
98th
$822.0M
78th
$5.8B
100th

Scores & forensic checks

15 measures
MeasureMDTSYKABT
IS score 64
80th
74
93rd
57
67th
IS profitability 57
80th
72
95th
46
63rd
IS growth 55
41st
64
59th
28
11th
IS value 64
88th
52
77th
49
72nd
IS momentum 83
77th
90
86th
60
32nd
IS risk (safety) 65
42nd
100
62nd
80
52nd
IS quality 83
88th
87
95th
70
62nd
IS balance sheet 70
72nd
63
67th
62
65th
IS earnings quality 93
100th
78
93rd
72
72nd
IS cash flow 66
75th
70
77th
74
82nd
Piotroski F-score (0-9) 9
95th
9
95th
5
35th
Altman Z-score 2.9
47th
4.8
63rd
3.0
52nd
Beneish M-score −3.44
7th
−2.74
30th
−2.69
41st
Ohlson O-score −9.52
13th
−9.18
22nd
−8.73
28th
IS credit score 81
77th
81
78th
76
72nd

Per share

7 measures
MeasureMDTSYKABT
EPS, diluted (TTM) $4.07
87th
$9.66
100th
$3.11
75th
Book value per share $39.09
88th
$62.15
95th
$29.32
82nd
Tangible book per share −$2.01
18th
−$3.49
13th
−$0.40
28th
Revenue per share $29.21
77th
$66.94
95th
$26.73
73rd
FCF per share $4.77
83rd
$12.18
97th
$5.00
85th
Operating cash flow per share $6.25
83rd
$14.31
97th
$5.68
78th
Cash per share $6.86
80th
$9.01
87th
$3.21
57th

Size (TTM)

8 measures
MeasureMDTSYKABT
Market cap $121.2B
98th
$113.0B
97th
$181.5B
100th
Revenue $37.5B
98th
$25.8B
97th
$46.6B
100th
EBITDA $10.2B
98th
$6.7B
97th
$11.0B
100th
Net income $5.2B
98th
$3.7B
97th
$5.4B
100th
Free cash flow $6.1B
98th
$4.7B
97th
$8.7B
100th
Total assets $93.3B
98th
$47.9B
97th
$109.2B
100th
Shareholders' equity $50.2B
98th
$24.0B
95th
$51.1B
100th
Employees 95,000
98th
56,000
95th
115,000
100th

Price performance

9 measures
MeasureMDTSYKABT
1 day −0.7% +0.5% +0.2%
1 week +7.1% +6.3% +6.0%
1 month +3.0% +5.5% +2.6%
3 months +14.7% −7.7% +3.2%
6 months +11.8% −14.2% +8.3%
Year to date +1.2% −15.4% −15.1%
1 year +2.7% −20.3% −19.0%
3 years, cumulative +43.4% +15.4% +18.3%
5 years, cumulative −11.2% +16.5% −4.1%

Technicals

4 measures
MeasureMDTSYKABT
RSI 14 64.6 58.9 59.5
From 52-week high −7.9% −24.9% −20.6%
From 52-week low +31.5% +10.4% +28.0%
Beta 0.57 0.78 0.58
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms